Lexicon Pharmaceuticals (LXRX) Cut to Sell at ValuEngine

Share on StockTwits

Lexicon Pharmaceuticals (NASDAQ:LXRX) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report issued on Monday.

Several other equities analysts have also recently commented on the company. Wedbush upped their price target on Lexicon Pharmaceuticals from $36.00 to $38.00 and gave the company an “outperform” rating in a report on Monday, March 4th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Monday. BidaskClub raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 17th. Gabelli cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 13th. Finally, Citigroup reaffirmed a “buy” rating and issued a $14.00 price target on shares of Lexicon Pharmaceuticals in a report on Tuesday, January 22nd. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $17.13.

Lexicon Pharmaceuticals stock traded down $0.54 during trading hours on Monday, hitting $5.66. The stock had a trading volume of 2,712,224 shares, compared to its average volume of 1,008,978. The stock has a market cap of $658.87 million, a price-to-earnings ratio of -4.96 and a beta of 0.70. Lexicon Pharmaceuticals has a fifty-two week low of $4.25 and a fifty-two week high of $13.97.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.12. The firm had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $13.33 million. Lexicon Pharmaceuticals had a negative return on equity of 911.43% and a negative net margin of 192.53%. The company’s revenue for the quarter was down 49.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.27) EPS. As a group, sell-side analysts expect that Lexicon Pharmaceuticals will post -0.26 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of LXRX. Pegasus Asset Management Inc. acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth approximately $66,000. Paloma Partners Management Co acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth approximately $73,000. CWM Advisors LLC raised its holdings in shares of Lexicon Pharmaceuticals by 30.2% in the 4th quarter. CWM Advisors LLC now owns 13,059 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 3,030 shares in the last quarter. D.A. Davidson & CO. acquired a new position in shares of Lexicon Pharmaceuticals in the 4th quarter worth approximately $87,000. Finally, Metropolitan Life Insurance Co. NY raised its holdings in shares of Lexicon Pharmaceuticals by 409.3% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 14,760 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 11,862 shares in the last quarter. 99.16% of the stock is owned by institutional investors and hedge funds.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Further Reading: What is a stock split?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Brokerages Anticipate Reata Pharmaceuticals Inc  to Announce -$0.97 Earnings Per Share
Zacks: Brokerages Anticipate Reata Pharmaceuticals Inc to Announce -$0.97 Earnings Per Share
NPER  Market Capitalization Achieves $222,981.00
NPER Market Capitalization Achieves $222,981.00
Centurylink  Hits New 12-Month Low at $11.51
Centurylink Hits New 12-Month Low at $11.51
Core Laboratories  Updates Q2 2019 Earnings Guidance
Core Laboratories Updates Q2 2019 Earnings Guidance
Brightcove  Updates FY 2019 Earnings Guidance
Brightcove Updates FY 2019 Earnings Guidance
Super Game Chain  Price Up 15.7% Over Last Week
Super Game Chain Price Up 15.7% Over Last Week


© 2006-2019 Ticker Report